In a recent SEC filing, major investment firm Farallon Capital Management disclosed a substantial new position in Revolution Medicines (RVMD). The filing, which reflects holdings as of March 31, 2026, revealed that Farallon acquired 13.60 million shares, valued at approximately $1.32 billion. This new stake gives Farallon a significant 7.54% weight in the biotechnology company within its portfolio.
It is important to note that 13F filings are submitted to the SEC quarterly and released with a delay, so this disclosure does not represent a real-time trade. The investment period coincided with positive developments for Revolution Medicines, which has since announced that its New Drug Application for daraxonrasib for previously treated metastatic pancreatic cancer was accepted for review by the U.S. FDA.